Amgen (AMGN) analysis

Loading the Vaultflake…

Health is the debt of several lines, not of a factory that cannot be copied. Quality separates the margin of one line from another, and from the price that gives way with the biosimilar. Growth follows covered treatments, not the launch headline. P/E is read against a year of many sales, not against that peak. Shareholder return is the dividend, checked against cash. Do not read it as a rising dividend already closed.

The P/E of a year of many sales is not the earnings if the payer cuts back. EV/EBITDA is read with the biosimilar, which is the price cut. Do not use Gilead's multiple, which lives on the antiviral, as if cholesterol and HIV were the same book. A dash if the AMGN cache is cold.

Limits of this report

Not advice on Amgen. Vaultflake does not describe how the medicine is made or how it is given, and does not state the patent date. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report